Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

PRESS: Rainmaker Q&A: Goodwin’s Ilan Nissan (<i>Law360</i>)

main

11_11_16 PRESS_Rainmaker Q_A_Goodwins Ilan

PRESS: Rainmaker Q&A: Goodwin’s Ilan Nissan (Law360)

PRESS: Rainmaker Q&A: Goodwin’s Ilan Nissan (Law360)

Related Content

FDIC Board of Directors Issues a Final Rule Pursuant to Special Assessment

FinCEN Finalizes Rule on Use of FinCEN Identifiers in Beneficial Ownership Information Reporting

FDIC Announces Iowa Bank Failure – 5th Bank to Fail in 2023

Federal Reserve Requests Comment on a Proposal to Lower The Maximum Interchange Fee that a Large Debit Card Issuer Can Receive for a Debit Card Transaction

CFPB Proposes Rule to Accelerate Shift to Open Banking

FDIC Proposes Guidelines for Corporate Governance and Risk Management

OIG: Review of the Supervision of Silvergate Bank

SEC Approves Revised Privacy Act Rule

The British Legal Awards Name Goodwin Editor’s Choice Law Firm of the Year

Miro acquires Freehand app from InVision

Q32 Bio and Homology Medicines To Merge

JUVE 2023/2024 Recommends Goodwin Partners and Practices Across Germany

Graphite Bio and LENZ Therapeutics To Merge

Alkermes Completes Separation of Oncology Business

Goodwin Advises Thoma Bravo on $1.8 Billion Acquisition of NextGen Healthcare, Inc.

EQRx’s Acquisition by Revolution Medicines is Complete

Private Equity

Mergers & Acquisitions